Interferon alpha-2c therapy of patients with chronic myelogenous leukemia: Long-term results of a multicenter phase II study

Annals of Hematology

Volumn 72, Issue 6, 1996, Pages 349-355

  Thaler, J ^a   Gastl, G ^a   Fluckinger, T ^a   Niederwieser, D ^a   Huber, H ^g   Seewann, H ^b   Sill, H ^c   Lang, A ^d   Falk, M ^e   Duba, C ^e   Utermann, G ^e   Kuhr T ^a   Aulitzky, W ^f   Huber, C ^f  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY HOSPITAL GRAZ   (Austria)

^d Landeskrankenhaus Feldkirch   (Austria)

^e UNIVERSITY OF INNSBRUCK   (Austria)

^f UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^g NONE

Author keywords

CML; Cytogenetic response; Interferon alpha

Indexed keywords

ALPHA2C INTERFERON; RECOMBINANT ALPHA2C INTERFERON;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CYTOGENETICS; DOSE RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; RISK FACTOR; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL TIME;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; CHILD; CYTOGENETICS; FEMALE; HUMANS; INTERFERON TYPE I, RECOMBINANT; LEUKEMIA, MYELOID, CHRONIC; LONGITUDINAL STUDIES; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REMISSION INDUCTION; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 8944241772     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002770050185     Document Type: Article

References (31)

1. Alimena G, Morra E, Lazzarino M, et al (1988) Interferon alpha-2b as therapy for Ph-positive chronic myelogenous leukemia: a study of 82 patients treated with intermittent or daily administration. Blood 72:642-647
2. Allan NC, Richards SM, Shepherd PCA, on behalf of the UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia (1995) UK Medical Research Council randomised, multicentre trial of interferon-αn1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. Lancet 345:1392-1397
3. Anderson JR, Cain KC, Gelber RD (1983) Analysis of survival by tumor response. J Clin Oncol 1:710
4. Cox DR (1972) Regression models and life tables. J R Stat Soc [Ser B] 34:187-220
5. Devergie A, Biaise D, Attal M, for the French Society of Bone Marrow Graft (SFGM) (1995) Allogeneic bone marrow transplantation for chronic myeloid leukemia in first chronic phase: a randomized trial of busulfan-cytoxan versus cytoxantotal body irradation as preparative regimen: a report from the French Society of Bone Marrow Graft (SFGM). Blood 85:2263-2268
6. Gastl G, Aulitzky W, Tilg H, et al (1987) Dose-related effectiveness of alpha interferon in chronic myelogenous leukemia. Blut 54:251-252
7. Hehlmann R, Heimpel H, Hasford H, et al (1994) Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. Blood 84:4064-4077
8. Kantarjian HM, Keating MJ, Smith TL, et al (1990) Proposal for a simple synthesis prognostic staging system in chronic myelogenous leukemia. Am J Med 88:1-8
9. Kantarjian HM, Smith TL, O'Brien S, et al (1995) Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-a therapy. Ann Intern Med 122:254-261
10. Kloke O, Niederle N, Qiu JY, et al (1993) Impact of interferon alpha-induced cytogenetic improvement of survival in chronic myelogenous leukaemia. Br J Haematol 83:399-403
11. Koeffler HP, Golde DW (1981) Chronic myelogenous leukemia - new concepts. N Engl J Med 304:1201-1209
12. McGlave P (1990) Bone marrow transplants in chronic myelogenous leukemia: an overview of determinants of survival. Semin Hematol 27 (Suppl 4): 23-30
13. Miller AB, Hoogstraten B, Straquet, et al (1981) Reporting results of cancer treatment. Cancer 47:207-214
14. Niederle N, Kloke O, Doberauer C, et al (1986) α2-Interferon: erste Behandlungsergebnisse bei der chronisch myeloischen Leukämie. Dtsch Med Wochenschr 111:767-772
15. Ozer H, George SL, Schiffer CA, et al (1993) Prolonged subcutaneous administration of recombinant α2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: effect on remission duration and survival: Cancer and Leukemia Group B Study 8583. Blood 82:2975-2984
16. Sanchez A, Robinson WA, Cohn A, et al (1992) Low-dose a-interferon treatment of chronic myeloid leukemia. Am J Hematol 39:61-62
17. Schofield JR, Robinson WA, Murphy JR, et al (1994) Low doses of interferon-alpha are as effective as higher doses in inducing remissions and prolonging survival in chronic myeloid leukemia. Ann Intern Med 121:736-744
18. Sokal JE, Cox EB, Baccarani M, et al (1994) Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood 63:789-799
19. Speck B, Bortin MM, Champlin R, et al (1984) Allogeneic bone-marrow transplantation for chronic myelogenous leukaemia. Lancet 1:665-668
20. Talpaz M, McCredie KB, Mavligit GM, et al (1983) Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia. Blood 62:689-692
21. Talpaz M, Kantarjian HM, McCredie KB, et al (1986) Hematologic remission and cytogenetic improvement induced by recombinant human interferon-alpha in chronic myelogenous leukemia. N Engl J Med 314:1065-1069
22. Talpaz M, Kantarjian HM, McCredie KB, et al (1987) Clinical investigation of human alpha Interferon in chronic myelogenous leukemia. Blood 69:1280-1288
23. Talpaz M, Kantarjian HM, Kurzrock R, et al (1991) Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Ann Intern Med 114:532-538
24. Thaler J, Kühr T, Gastl G, et al (1991) Rekombinantes Interferon alpha-2c bei Ph-positiver chronisch myeloischer Leukämie. Ergebnisse einer multizentrischen Phase-II-Studie. Dtsch Med Wochenschr 116:721-728
25. Thaler J, Fluckinger T, Huber H, et al (1993) Treatment of 11 patients with chronic myelogenous leukemia with interferon-alpha-2c and low-dose cytosine arabinoside. Leuk Res 17:711-715
26. Thaler J, Gastl G, Fluckinger T, et al (1993) Treatment of chronic myelogenous leukemia with interferon alfa-2c: response rate and toxicity in a phase-II multicenter study. Semin Hematol 30 [Suppl 3]: 17-19
27. Thaler J, Fridrik M, Apfelbeck U, et al (1994) Interferon-alpha-2c and LD-Ara-C for the treatment of patients with CML: results of the Austrian multicenter phase-II study. Onkologie [Suppl] 2:151 (abstr 602)
28. The Italian Cooperative Study Group on Chronic Myeloid Leukemia (1992) A prospective comparison of α-IFN and conventional chemotherapy in Ph+ chronic myeloid leukemia: clinical and cytogenetic results at 2 years in 322 patients. Haematological (Pavia) 77:204-214
29. The Italian Cooperative Study Group on Chronic Myeloid Leukemia (1994) Interferon alfa 2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 330:820-825
30. Thomas ED. Clift RA, Fefer A, et al (1986) Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med 104:155-163
31. Yunis JJ (1981) New chromosome techniques in the study of human neoplasia. Hum Pathol 12:540-549